CLINICAL TRIAL

Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes Naoko Tajima1, Takashi Kadowaki2, Taro Okamoto3, Asako Sato3, Kotoba Okuyama3, Toshiomi Minamide4, Juan Camilo Arjona Ferreira5* ABSTRACT Aims/Introduction: Type 2 diabetes mellitus is a progressive disease that frequently requires patients to use more than one oral antihyperglycemic agent to achieve adequate glycemic control. The present multicenter, randomized study assessed the efficacy and safety of the addition of sitagliptin to ongoing voglibose monotherapy (0.2–0.3 mg three times daily) in Japanese patients with type 2 diabetes mellitus who had inadequate glycemic control (glycated hemoglobin ≥6.9% and 1.5 mg/dL in men, >1.3 mg/dL in women) or increased alanine aminotransferase or aspartate aminotransferase more than twofold the upper limit of normal, hemoglobin

Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes.

Type 2 diabetes mellitus is a progressive disease that frequently requires patients to use more than one oral antihyperglycemic agent to achieve adequ...
228KB Sizes 1 Downloads 4 Views